Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12697214 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL12697193 | 0.95 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL24548234 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA4HRH3JAK3CHRM4 | |
| SCHEMBL7187294 | 0.82 | ALDH1A1 (0.50) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL29739626 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA4HRH3JAK3CHRM4 | |
| SCHEMBL24548206 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA4HRH3JAK3CHRM4 | |
| SCHEMBL29177381 | 0.82 | CHRNB2 (0.44) | CHRNB2CHRNA4HRH3JAK3CHRM4 | |
| SCHEMBL12695040 | 0.80 | CHRM4 (0.38) | HRH3JAK3CHRM4DYRK1ASMPD3 | |
| SCHEMBL12695044 | 0.80 | CHRM4 (0.38) | HRH3JAK3CHRM4DYRK1ASMPD3 | |
| SCHEMBL24562764 | 0.79 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ1, KCNC1 | CHRNB2 202/4885CHRNA4 142/4885CHRNB1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.